153 related articles for article (PubMed ID: 25595893)
1. Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer.
Liu D; Chang CH; Gold DV; Goldenberg DM
Oncotarget; 2015 Feb; 6(6):4274-85. PubMed ID: 25595893
[TBL] [Abstract][Full Text] [Related]
2. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.
Gold DV; Newsome G; Liu D; Goldenberg DM
Mol Cancer; 2013 Nov; 12(1):143. PubMed ID: 24257318
[TBL] [Abstract][Full Text] [Related]
3. Identification of HLA-A*0201- and A*2402-restricted epitopes of mucin 5AC expressed in advanced pancreatic cancer.
Yamazoe S; Tanaka H; Iwauchi T; Yoshii M; Ito G; Amano R; Yamada N; Sawada T; Ohira M; Hirakawa K
Pancreas; 2011 Aug; 40(6):896-904. PubMed ID: 21697763
[TBL] [Abstract][Full Text] [Related]
4. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.
Gold DV; Karanjawala Z; Modrak DE; Goldenberg DM; Hruban RH
Clin Cancer Res; 2007 Dec; 13(24):7380-7. PubMed ID: 18094420
[TBL] [Abstract][Full Text] [Related]
5. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study.
Kaur S; Smith LM; Patel A; Menning M; Watley DC; Malik SS; Krishn SR; Mallya K; Aithal A; Sasson AR; Johansson SL; Jain M; Singh S; Guha S; Are C; Raimondo M; Hollingsworth MA; Brand RE; Batra SK
Am J Gastroenterol; 2017 Jan; 112(1):172-183. PubMed ID: 27845339
[TBL] [Abstract][Full Text] [Related]
6. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.
Shi C; Merchant N; Newsome G; Goldenberg DM; Gold DV
Arch Pathol Lab Med; 2014 Feb; 138(2):220-8. PubMed ID: 24476519
[TBL] [Abstract][Full Text] [Related]
7. GLI1 facilitates the migration and invasion of pancreatic cancer cells through MUC5AC-mediated attenuation of E-cadherin.
Inaguma S; Kasai K; Ikeda H
Oncogene; 2011 Feb; 30(6):714-23. PubMed ID: 20972463
[TBL] [Abstract][Full Text] [Related]
8. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma.
Gold DV; Gaedcke J; Ghadimi BM; Goggins M; Hruban RH; Liu M; Newsome G; Goldenberg DM
Cancer; 2013 Feb; 119(3):522-8. PubMed ID: 22898932
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models.
Patel SP; Bristol A; Saric O; Wang XP; Dubeykovskiy A; Arlen PM; Morse MA
Cancer Immunol Immunother; 2013 Jun; 62(6):1011-9. PubMed ID: 23591984
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of mucins (MUC1, MUC2 and MUC5AC) expression profile in endoscopic ultrasound-guided fine-needle aspiration specimens of the pancreas.
Wang Y; Gao J; Li Z; Jin Z; Gong Y; Man X
Int J Cancer; 2007 Dec; 121(12):2716-22. PubMed ID: 17708554
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated MUC5AC stimulates in vivo tumorigenicity of human pancreatic cancer.
Hoshi H; Sawada T; Uchida M; Saito H; Iijima H; Toda-Agetsuma M; Wada T; Yamazoe S; Tanaka H; Kimura K; Kakehashi A; Wei M; Hirakawa K; Wanibuchi H
Int J Oncol; 2011 Mar; 38(3):619-27. PubMed ID: 21249315
[TBL] [Abstract][Full Text] [Related]
12. Development of a serum biomarker assay that differentiates tumor-associated MUC5AC (NPC-1C ANTIGEN) from normal MUC5AC.
Luka J; Arlen PM; Bristol A
J Biomed Biotechnol; 2011; 2011():934757. PubMed ID: 21197415
[TBL] [Abstract][Full Text] [Related]
13. Mapping of the 45M1 epitope to the C-terminal cysteine-rich part of the human MUC5AC mucin.
Lidell ME; Bara J; Hansson GC
FEBS J; 2008 Feb; 275(3):481-9. PubMed ID: 18167142
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of immunohistochemical staining for MUC5AC in differentiating primary pancreatic cancer from pancreatic metastasis of breast cancer.
Yamashita H; Kurita A; Azuma S; Kudo Y; Matsuzaki N; Yazumi S
Diagn Cytopathol; 2019 Oct; 47(10):1037-1041. PubMed ID: 31169985
[TBL] [Abstract][Full Text] [Related]
15. Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma.
Pan S; Chen R; Tamura Y; Crispin DA; Lai LA; May DH; McIntosh MW; Goodlett DR; Brentnall TA
J Proteome Res; 2014 Mar; 13(3):1293-306. PubMed ID: 24471499
[TBL] [Abstract][Full Text] [Related]
16. Predictive Value of MUC5AC Signature in Pancreatic Ductal Adenocarcinoma: A Hypothesis Based on Preclinical Evidence.
Manne A; Kasi A; Esnakula AK; Paluri RK
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175794
[TBL] [Abstract][Full Text] [Related]
17. RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells.
Yamazoe S; Tanaka H; Sawada T; Amano R; Yamada N; Ohira M; Hirakawa K
J Exp Clin Cancer Res; 2010 May; 29(1):53. PubMed ID: 20492722
[TBL] [Abstract][Full Text] [Related]
18. Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology.
Han L; Pansare V; Al-Abbadi M; Husain M; Feng J
Diagn Cytopathol; 2010 May; 38(5):333-6. PubMed ID: 19856421
[TBL] [Abstract][Full Text] [Related]
19. MUC5AC mucin gene regulation in pancreatic cancer cells.
Kato S; Hokari R; Crawley S; Gum J; Ahn DH; Kim JW; Kwon SW; Miura S; Basbaum CB; Kim YS
Int J Oncol; 2006 Jul; 29(1):33-40. PubMed ID: 16773182
[TBL] [Abstract][Full Text] [Related]
20. Quantitative analysis of MUC1 and MUC5AC mRNA in pancreatic juice for preoperative diagnosis of pancreatic cancer.
Ohuchida K; Mizumoto K; Yamada D; Fujii K; Ishikawa N; Konomi H; Nagai E; Yamaguchi K; Tsuneyoshi M; Tanaka M
Int J Cancer; 2006 Jan; 118(2):405-11. PubMed ID: 16052519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
